Clinical Trials Logo
  1. Home
  2. Post-Herpetic Neuralgia
  3. NCT03094195

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) — EMPHENE  

Post-herpetic Neuralgia Clinical Trial

Official title:
A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

Clinical Trial Summary

This study was designed to characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN).

Clinical Trial Description

This was an interventional, randomized, parallel, placebo-controlled, dose ranging, double-blind treatment study consisting of 3 periods i.e. Screening, Treatment, and Treatment withdrawal. The study was planned in two cohorts. The initial cohort had three treatment arms i.e. Placebo b.i.d., EMA401 25 mg b.i.d., or EMA401 100 mg b.i.d. Following an unblinded safety review by an independent DMC, the second cohort was to have been initiated with an additional treatment arm i.e. EMA401 300 mg b.i.d.. Due to the premature study termination, the second cohort was not initiated. At the end of treatment period the 25mg BID and 100mg BID arms were re-randomized (1:1) to the same treatment or placebo. Placebo arm stayed on placebo. The planned duration of treatment period was 12 weeks and 1 week of treatment withdrawal at the end of treatment period. The study was terminated early due to pre-clinical toxicity data that became available after start of trial. Novartis implemented a Urgent Safety Measure (USM) which instructed sites to discontinue study treatment immediately and to have all patients return for additional laboratory assessments (full hematology including coagulation and clinical chemistry panel). Safety data from the USM was presented as a separate outcome measure table and not included in the Adverse Event section. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03094195
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 2
Start date June 27, 2017
Completion date March 7, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT01944150 - Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis N/A
Completed NCT00159666 - Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia Phase 4
Completed NCT00305357 - Evolution of Pain From Herpes Zoster
Not yet recruiting NCT03120962 - Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia N/A
Completed NCT02701374 - Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia Phase 2
Completed NCT02318719 - DS-5565 Phase III Study for Post-herpetic Neuralgia N/A
Completed NCT01752699 - Methadone in Post-Herpetic Neuralgia Pain Phase 3
Completed NCT01250561 - Reduction of Postherpetic Neuralgia in Herpes Zoster N/A
Completed NCT02607280 - DS-5565 Phase III Study for Renal Impairment in Japanese Subjects Phase 3
Completed NCT01037088 - Effects of Vaporized Marijuana on Neuropathic Pain Phase 1/Phase 2
Completed NCT02633306 - Transcranial Magnetic Stimulation for Facial Pain N/A
Recruiting NCT05593237 - Transcranial Magnetic Stimulation for Chronic Neuropathic Pain N/A
Completed NCT01848730 - Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia Phase 2